Astral Systems, a British DeepTech firm pioneering multi-state fusion (MSF) technology, has secured €26 million (£23 million) in Series A funding in order to bring critical medical isotopes to market by early 2027, scaling the production of its modular MSF reactors, and advancing fusion research.
This first close investment was led by Mercia Ventures and supported by prominent tech investors including Tees River, Daphni, and Blast Club, alongside previous investors Speedinvest and Playfair.
Talmon Firestone, CEO and co-founder of Astral Systems, says: “We are rewriting how we approach fusion and, in doing so, redefining what it means to be a fusion company. This is evident in our novel technology and its near-term applications in modern medicine, as well as facilitating the search for hybrid energy.
“With this new funding we can accelerate our ambition of building a profitable, impactful fusion business, and build on the momentum of the past 12 months with the backing of our investors.”
Lee Lindley, who led the investment on behalf of Mercia Ventures, adds: “We’re incredibly proud to have led this investment into Astral Systems are excited about working with Talmon and Tom. Astral’s technology has the potential to transform the manufacturing and supply of medical isotopes, which are vitally important for diagnostic and therapeutic purposes. Astral Systems is a perfect example of the bold ideas that Mercia likes to back.”
Established in 2021 by co-founders Talmon Firestone and Dr Tom Wallace-Smith, Astral Systems is a DeepTech firm that invented and commercialised its MSF technology, a new type of nuclear fusion with allegedly unprecedented performance.
The firm firmly believes that their fusion capabilities put it in a strong position to tackle the fragile supply chain and potential global shortages of medical radioisotopes that severely impact cancer diagnosis and treatments.
With this new capital and its new facility being developed at the former Berkeley Power Station, the firm intends to run multiple next-generation compact fusion reactors at full capacity by the end of 2026.
The performance of these compact reactors enables the goal of establishing the highest-flux, highest-intensity, continuously operable private fusion volumetric neutron source in the world.
The firm says that if they are successful l, this will revive UK medical isotope production and provide an evergreen supply of radioisotopes for research, medical, and industrial applications.
With over 50 million nuclear medicine procedures performed each year, demand for radioisotopes is set to continue to rise. Astral Systems is well-positioned to be a leading source of crucial medical isotopes that support modern medicine.
The company’s growth plans and the intention to reach profitability within 2027 are supported by the market traction and growth seen in the past 12 to 24 months:
- Generating Revenue: Astral Systems has established three commercial fusion facilities and generated more than €3.4 million (£3 million) in revenue via research contracts that utilise MSF technology.
- Team Growth: Plans to scale from 23 employees to over 40 by the end of 2026. NASA Laureate and nuclear physicist Dr. Theresa Benyo recently joined as Chief Research Officer alongside Chief Scientist Dr. Mahmoud Bakr.
- Isotope Production Breakthrough: In partnership with both McMaster University and Institute for Energy and Nuclear Research (IPEN) in Brazil, Astral Systems has been working on producing Actinium-225 and Lead-212, two highly sought-after radioisotopes critical to new cancer treatments.
- Nuclear fuel cycle testing: Astral Systems, in partnership with the University of Bristol, has completed over a year of tritium breeder blanket research. The team has also recently won a UK grant to explore Astral’s technology as a testbed for advanced fission fuels.
This recent investment brings the total funding of Astral Systems to over €32 million (£28 million).
